Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 275.96% | 130.61% | -26.51% | 349.95% | -417.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,363.66% | 56.03% | 24.74% | 117.19% | -79.01% |
| Operating Income | -1,363.66% | -56.03% | -24.74% | -117.19% | 79.01% |
| Income Before Tax | -626.88% | -59.73% | 130.97% | -164.60% | 148.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -626.88% | -59.73% | 130.97% | -164.60% | 148.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -626.88% | -59.73% | 130.97% | -164.60% | 148.33% |
| EBIT | -1,363.66% | -56.03% | -24.74% | -117.19% | 79.01% |
| EBITDA | -1,413.39% | -56.45% | -25.49% | -132.39% | 79.45% |
| EPS Basic | -772.66% | 99.26% | 100.15% | 98.69% | 111.65% |
| Normalized Basic EPS | -6,825.00% | 99.26% | 100.18% | 98.22% | 101.46% |
| EPS Diluted | -775.78% | 99.26% | 100.15% | 98.69% | 111.65% |
| Normalized Diluted EPS | -6,825.00% | 99.26% | 100.18% | 98.22% | 101.46% |
| Average Basic Shares Outstanding | -21.85% | 21,420.10% | 21,196.20% | 20,159.01% | 316.09% |
| Average Diluted Shares Outstanding | -21.85% | 21,420.10% | 21,196.20% | 20,159.01% | 316.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |